Published in Int J Cancer on February 01, 2002
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Subcellular localization of Mdm2 expression and prognosis of breast cancer. Int J Clin Oncol (2013) 0.87
Modulation of mammalian cell growth and death by prokaryotic and eukaryotic cytochrome c. Proc Natl Acad Sci U S A (2004) 0.81
Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials (2013) 0.81
The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget (2016) 0.79
DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell lines. Int J Clin Exp Pathol (2014) 0.75
Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol (2016) 0.75
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. PLoS One (2017) 0.75
Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One (2008) 8.97
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell (2008) 5.88
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ (2006) 4.79
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol (2008) 4.24
Retracted Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol (2009) 3.84
Gastric adenocarcinoma: review and considerations for future directions. Ann Surg (2005) 3.83
Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol (2007) 3.58
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol (2003) 3.56
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res (2009) 3.06
Randomized controlled trial of the effects of print materials and step pedometers on physical activity and quality of life in breast cancer survivors. J Clin Oncol (2007) 2.65
Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol (2007) 2.53
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol (2006) 2.51
A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell (2013) 2.46
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol (2008) 2.31
Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 2.23
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
Effects of an oncologist's recommendation to exercise on self-reported exercise behavior in newly diagnosed breast cancer survivors: a single-blind, randomized controlled trial. Ann Behav Med (2004) 2.04
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol (2008) 1.99
Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev (2003) 1.89
Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep (2002) 1.79
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol (2008) 1.76
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol (2010) 1.74
Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell (2004) 1.71
Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J Med Chem (2008) 1.69
A revised nomenclature for the human and rodent alpha-tubulin gene family. Genomics (2007) 1.68
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer. Breast Cancer Res Treat (2010) 1.65
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer (2007) 1.63
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res (2009) 1.62
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma (2002) 1.61
Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol (2012) 1.61
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. Am J Clin Oncol (2004) 1.60
Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS One (2009) 1.60
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther (2013) 1.60
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2011) 1.59
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 1.58
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet (2009) 1.55
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res (2002) 1.55
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res (2005) 1.51
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther (2005) 1.50
Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer (2009) 1.49
Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer? J Clin Oncol (2011) 1.48
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet (2012) 1.47
Gadd45a activation protects melanoma cells from ultraviolet B-induced apoptosis. J Invest Dermatol (2007) 1.47
Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial. Brain Behav Immun (2005) 1.45
A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma (2013) 1.43
Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions. Cancer (2007) 1.41
MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res (2002) 1.41
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol (2002) 1.37
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell (2013) 1.35
Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents (2005) 1.35
The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells (2010) 1.34
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther (2011) 1.33
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol (2008) 1.33
Prospective cohort study of lifetime physical activity and breast cancer survival. Int J Cancer (2009) 1.32
Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther (2009) 1.32
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer (2010) 1.31
Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation (2011) 1.30
Randomized controlled trial of exercise and blood immune function in postmenopausal breast cancer survivors. J Appl Physiol (1985) (2005) 1.29
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res (2007) 1.26
Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene (2003) 1.25
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol (2010) 1.25
Systematic mRNA analysis for the effect of MLH1 and MSH2 missense and silent mutations on aberrant splicing. Hum Mutat (2006) 1.25
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Predictors of supervised exercise adherence during breast cancer chemotherapy. Med Sci Sports Exerc (2008) 1.23
Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res (2009) 1.21
Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res (2002) 1.20
Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res (2010) 1.19
Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer. Lung Cancer (2006) 1.19
Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial. J Natl Cancer Inst (2013) 1.18
Physical exercise and immune system function in cancer survivors: a comprehensive review and future directions. Cancer (2002) 1.18